Pan-RAS Inhibition in Pancreatic Cancer: Practice-Changing Phase 3 Data and What Comes Next
Drs. Hornstein, Brown, and Grewal examine a groundbreaking phase 3 trial press release for a pan-RAS inhibitor in second-line metastatic pancreatic cancer, showing a striking doubling of overall survival compared with standard chemotherapy. They explain how targeting the active KRAS state represents a major shift from prior mutation-specific approaches, potentially benefiting up to 90% of […]
